MiR-146a promotes remyelination in a cuprizone model of demyelinating injury

Neuroscience. 2017 Apr 21:348:252-263. doi: 10.1016/j.neuroscience.2017.02.029. Epub 2017 Feb 23.

Abstract

The death of mature oligodendrocytes (OLs) which are the sole myelinating cells of the central nervous system (CNS), leads to demyelination and functional deficits. Currently, there is lack of effective remyelination therapies for patients with demyelinating diseases. MicroRNAs (miRNAs) mediate OL function. We hypothesized that miR-146a, by inactivating interleukin-1 receptor-associated kinase 1 (IRAK1), promotes differentiation of oligodendrocyte progenitor cells (OPCs) and thereby enhances remyelination. To test this hypothesis, a demyelination model induced by a cuprizone (CPZ) diet was employed, in which C57BL/6J mice were fed with a CPZ diet for 5weeks. After termination of CPZ diet, the mice were randomly treated with continuous infusion of miR-146a mimics or mimic controls into the corpus callosum for 7days. Compared to the mimic control, infusion of miR-146a mimics facilitated remyelination assessed by increased myelin basic proteins in the corpus callosum, which was associated with augmentation of newly generated mature OLs. Infusion of miR-146a mimics also substantially elevated miR-146a levels in the corpus callosum and fluorescently tagged miR-146a mimics were mainly detected in OPCs. Western blot and double immmunofluorescent staining analysis showed that the miR-146a treatment considerably reduced IRAK1 protein levels and the number of IRAK1-positive cells, respectively. Collectively, these data indicate that exogenous miR-146a enhances remyelination, possibly by promoting OPCs to differentiate into myelinated OLs via targeting IRAK1.

Keywords: IRAK1; cuprizone; miR-146a; oligodendrocyte; oligodendrocyte progenitor cells; remyelination.

MeSH terms

  • Animals
  • Corpus Callosum / drug effects*
  • Corpus Callosum / metabolism
  • Cuprizone
  • Demyelinating Diseases / chemically induced
  • Demyelinating Diseases / drug therapy*
  • Demyelinating Diseases / metabolism
  • Mice
  • Mice, Inbred C57BL
  • MicroRNAs / pharmacology
  • MicroRNAs / therapeutic use*
  • Neurogenesis / drug effects*
  • Oligodendroglia / drug effects

Substances

  • MicroRNAs
  • Mirn146 microRNA, mouse
  • Cuprizone